ISLET AFTER KIDNEY TRANSPLANTATION (IAK) IN PATIENTS WITH TYPE 1 DIABETES

这个子项目是许多利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 本研究旨在评价1型糖尿病患者肾移植后胰岛移植（IAK）的安全性和疗效。 患者必须既往接受过成功的肾移植，使用稳定的免疫抑制剂（包括西罗莫司、他克莫司和无皮质类固醇），并由移植肾病学家/外科医生转诊。 胰岛将在门静脉内移植。 将密切监测患者2年的不良事件发生率以及肾移植功能、血糖控制、胰岛素剂量需求、其他代谢变量、免疫反应和生活质量的变化。 胰岛移植有望改善血糖控制，从而改善患者的移植肾功能和生活质量。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study will evaluate the safety and efficacy of islet after kidney transplantation (IAK) in patients with type 1 diabetes. Patients must have previously received successful renal transplant with stable immunosuppression consisting of sirolimus, tacrolimus and no corticosteroids and be referred by a transplant nephrologist/surgeon. Islets will be transplanted intraportally. Patients will be monitored closely for two years for the occurrence of adverse events and changes in renal graft function, blood glucose control, insulin dose requirements, other metabolic variables, immunologic reactions and quality of life. Islet transplantation is expected to improve glycemic control and thereby improve the patient's renal graft function and quality of life.